CDK1 serves as a potential prognostic biomarker and target for lung cancer
CDK1 serves as a potential prognostic biomarker and target for lung cancer
复制标题
DOI：
10.1177/0300060519897508
复制
发表时间：
2020-02-01
影响因子：
1.6
通讯作者：
Hu, Danfei
中科院分区：
文献类型：
--
作者：
Li, Mingyao;He, Fenyi;Hu, Danfei
细胞和小鼠模型以及人体组织的证据表明，细胞周期蛋白依赖性激酶1（CDK 1）参与肺癌（LC）的肿瘤发生。然而，不同类型的表达模式和预后结果的CDK 1需要进一步的analysis.MethodsIn目前的研究中，我们评估CDK 1的表达和LC患者的结果使用的数据从Oncomine，GEPIA和Kaplan-Meier绘图仪数据库。此外，通过使用cBioPortal数据库分析CDK 1基因中的突变。结果CDK 1在肺腺癌和肺鳞癌组织中的表达明显高于正常肺组织。此外，CDK 1表达与疾病进展有关。生存分析表明，上调CDK 1相关的总生存率差，低的第一次进展，和进展后生存的患者与LC.ConclusionsOur结果表明，CDK 1是一个潜在的临床靶点和预后的生物标志物与LC患者。
ObjectiveEvidence from cell and mouse models and human tissues suggests that cyclin dependent kinase 1 (CDK1) is involved in lung cancer (LC) tumorigenesis. However, the different types of expression patterns and prognostic results of CDK1 need further analysis.MethodsIn the current study, we assessed CDK1 expression and LC patient outcomes using data from the Oncomine, GEPIA, and Kaplan-Meier Plotter databases. Additionally, mutations in the CDK1 gene were analyzed by using the cBioPortal database. The expression of CDK1 was verified by real-time quantitative PCR using the Human Protein Atlas database and human tissues.ResultsExpression of CDK1 was higher in lung adenocarcinoma and squamous cell lung carcinoma tissues than in normal lung samples. Moreover, CDK1 expression was linked to disease progression. Survival analysis indicated that upregulation of CDK1 was related to poor overall survival, low first progression, and post-progression survival in patients with LC.ConclusionsOur results indicate that CDK1 is a potential clinical target and prognostic biomarker for patients with LC.